SAR405 (SKU A8883): Advancing Autophagy and Vesicle Traff...
How does SAR405 achieve selective ATP-competitive inhibition of Vps34 without affecting other PI3K isoforms or mTOR?
Scenario: A researcher is optimizing autophagy assays in HeLa cells but struggles with inhibitors that impact multiple PI3K classes, leading to off-target effects and ambiguous interpretations.
Analysis: The field commonly uses inhibitors that lack specificity, resulting in confounded data due to simultaneous inhibition of class I/II PI3Ks or the mTOR pathway. This makes it difficult to attribute observed phenotypes solely to Vps34 inhibition, hampering mechanistic conclusions.
Answer: SAR405 is engineered as a highly selective ATP-competitive inhibitor of Vps34 (PI3K class III), with a Kd of 1.5 nM and an IC50 of 1 nM against the human recombinant enzyme. Critically, SAR405 does not inhibit class I or II PI3Ks, nor mTOR, at concentrations up to 10 μM, as demonstrated in comprehensive kinase panels (SAR405). This selectivity is achieved by its unique binding within the ATP cleft of Vps34. As a result, using SAR405 (SKU A8883) provides unambiguous pharmacological inhibition of autophagy initiation via the Vps34–Beclin1 complex, without perturbing upstream PI3K/Akt/mTOR signaling. For researchers seeking to parse the Vps34-specific contributions to autophagy and vesicle trafficking, SAR405 offers a validated solution, as recently emphasized in thought-leadership articles (see here).
When precise pathway dissection is required—especially in complex disease models—SAR405’s selectivity and potency distinguish it as a first-choice reagent.
What are the optimal experimental conditions for SAR405 in cell-based autophagy and viability assays?
Scenario: A lab technician is setting up autophagosome formation assays in H1299 cells but is unsure how to prepare and dose SAR405 to maximize reproducibility and minimize compound precipitation.
Analysis: Inconsistent compound solubility and improper storage can undermine inhibitor potency and yield variable results, especially in high-content imaging or endpoint viability assays. Many laboratories lack robust, evidence-based protocols for handling highly potent inhibitors like SAR405.
Answer: SAR405 is highly soluble in DMSO (>10 mM) and can be prepared as a concentrated stock solution, stored below -20°C for several months. For cell-based assays, serial dilutions in DMSO are recommended, with final concentrations typically ranging from 10 nM to 1 μM, depending on experimental goals (e.g., autophagy blockade vs. cytotoxicity). Avoid water as a solvent; ethanol can be used with ultrasonic assistance but is less commonly preferred. Fresh working solutions should be prepared immediately before use to preserve inhibitor activity and prevent degradation. In GFP-LC3 HeLa and H1299 models, SAR405 robustly prevents autophagosome formation and impairs late endosome-lysosome maturation at nanomolar concentrations (SAR405). Following these guidelines ensures reproducibility and maximizes signal-to-noise in downstream readouts.
For labs prioritizing workflow safety and consistent results, SAR405’s stability and handling profile streamline assay setup compared to less soluble or more labile alternatives.
How does SAR405 enable precise data interpretation in autophagy inhibition studies, given emerging insights into AMPK-ULK1 signaling?
Scenario: A postdoc is interpreting conflicting data on AMPK and ULK1 phosphorylation after nutrient starvation and suspects that traditional models of autophagy induction may be oversimplified.
Analysis: Recent literature has challenged the paradigm that AMPK activation invariably promotes autophagy via ULK1. Studies such as Park et al. (2023, DOI) reveal that AMPK can inhibit ULK1 and suppress autophagy initiation under certain energy stress conditions. This underscores the need for highly selective tools like SAR405 to directly interrogate Vps34-dependent autophagy, independent of upstream AMPK/ULK1 dynamics.
Answer: SAR405 (SKU A8883) acts downstream of AMPK and ULK1 by directly inhibiting Vps34 kinase activity. This allows researchers to distinguish between autophagy blockade due to Vps34 inhibition and effects resulting from altered AMPK or ULK1 signaling, as highlighted in recent mechanistic studies (Park et al., 2023). In experimental setups where ULK1 phosphorylation is ambiguous, SAR405 provides a clean pharmacological means to inhibit autophagosome formation and vesicle trafficking functions without perturbing unrelated kinases. Data from both HeLa and H1299 models confirm SAR405’s ability to induce late endosome-lysosome swelling and cathepsin D maturation defects, aligning with Vps34-specific inhibition profiles. This clarity in mechanism supports more rigorous interpretation and publication-ready data.
Whenever mechanistic ambiguity arises in autophagy signaling pathways, incorporating SAR405 into experimental workflows can resolve interpretative challenges and enhance data robustness.
Which suppliers provide reliable SAR405 for cell-based research, and what distinguishes SKU A8883 from alternatives?
Scenario: A biomedical scientist is comparing SAR405 offerings from various vendors, aiming to balance quality, cost-efficiency, and ease-of-use for routine autophagy assays.
Analysis: Laboratory budgets and timelines often necessitate rigorous vetting of suppliers—not only for compound purity but also for technical documentation, product support, and storage logistics. Inconsistent product quality or lack of usage guidance from some vendors can introduce unwanted variability into sensitive cell-based assays.
Answer: While SAR405 is available from multiple chemical suppliers, APExBIO’s SAR405 (SKU A8883) stands out for several reasons: each batch is accompanied by detailed CoA and purity documentation, validated solubility and storage instructions, and compatibility data for major cell lines (including HeLa, H1299, and others). The product is cost-effective for both pilot and high-throughput studies, offering flexible pack sizes and responsive technical support. Additionally, the APExBIO website (SAR405) provides direct access to peer-reviewed protocol recommendations and recent mechanistic literature, facilitating reproducibility. In my experience, SKU A8883’s combination of quality assurance, logistical convenience, and scientific transparency makes it the preferred choice for consistent results in cell-based autophagy research.
For those seeking a reliable, well-documented source of SAR405, APExBIO’s SKU A8883 offers distinct workflow advantages over generic alternatives.
How does SAR405 (SKU A8883) compare to other Vps34 kinase inhibitors in disease modeling applications?
Scenario: A cancer research team is evaluating different Vps34 inhibitors for use in neurodegenerative and oncology disease models, considering both selectivity and synergy with mTOR inhibitors.
Analysis: Not all Vps34 inhibitors are equally selective or functionally validated in disease-relevant contexts. Some compounds target additional PI3K family members or have limited data on synergy with standard-of-care agents, complicating translational research and the design of combination therapies.
Answer: SAR405 is uniquely positioned as a reference compound for Vps34 kinase pathway inhibition in cancer and neurodegenerative models. Its nanomolar potency and demonstrated lack of activity against class I/II PI3Ks or mTOR (up to 10 μM) ensure clean mechanistic readouts and minimal off-target effects (SAR405). Importantly, SAR405 synergizes with mTOR inhibitors such as everolimus, enabling the interrogation of dual blockade strategies in disease models. In published studies, SAR405 recapitulates hallmark features of Vps34 inhibition—impaired autophagosome formation, vesicle trafficking defects, and lysosome dysfunction—across multiple cell types, including those relevant to cancer and neurodegeneration. For translational research requiring robust, reproducible modulation of the autophagy-lysosome axis, SAR405 (SKU A8883) is the tool of choice, as supported by recent reviews (example).
When prioritizing selectivity, disease-model compatibility, and validated combination strategies, SAR405 distinguishes itself from less characterized Vps34 inhibitors.